Substance / Medication

Thiamine pyrophosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Alcoholic polyneuropathy

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

A Trial of Thiamin Supplementation in Patients With Heart Failure

NCT00959075Phase 4Completed70 enrolled

The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

NCT03746106Phase 4Completed7 enrolled

View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Relationship of blood thiamine pyrophosphate to plasma phosphate and the response to enteral nutrition plus co-administration of intravenous thiamine during critical illness.

Collie Jake T B, Jiang Alice, Abdelhamid Yasmine Ali et al. · J Hum Nutr Diet · 2023

PMID: 36919646RCT

Evaluation of whole blood thiamine pyrophosphate concentrations in critically ill patients receiving chronic diuretic therapy prior to admission to Turkish intensive care units: A pragmatic, multicenter, prospective study.

Gundogan Kursat, Sahin Gulsah G, Ergul Serap S et al. · J Crit Care · 2023

PMID: 37186999Observational

An investigation of the effect of thiamine pyrophosphate on cisplatin-induced oxidative stress and DNA damage in rat brain tissue compared with thiamine: thiamine and thiamine pyrophosphate effects on cisplatin neurotoxicity.

Turan M I, Cayir A, Cetin N et al. · Hum Exp Toxicol · 2014

PMID: 23632005Observational

The protective effect of thiamine pyrophosphate, but not thiamine, against cardiotoxicity induced with cisplatin in rats.

Coskun Resit, Turan Mehmet Ibrahim, Turan Isil Siltelioglu et al. · Drug Chem Toxicol · 2014

PMID: 24215635Observational

A comparative investigation of biochemical and histopathological effects of thiamine and thiamine pyrophosphate on ischemia-reperfusion induced oxidative damage in rat ovarian tissue.

Demiryilmaz Ismail, Sener Ebru, Cetin Nihal et al. · Arch Pharm Res · 2013

PMID: 23760618Observational

Biochemically and histopathologically comparative review of thiamine's and thiamine pyrophosphate's oxidative stress effects generated with methotrexate in rat liver.

Demiryilmaz Ismail, Sener Ebru, Cetin Nihal et al. · Med Sci Monit · 2012

PMID: 23197226ObservationalFull text (PMC)

Utility of Whole Blood Thiamine Pyrophosphate Evaluation in-Related Diseases.

Bugiardini Enrico, Pope Simon, Feichtinger René G et al. · J Clin Med · 2019

PMID: 31288420Case ReportFull text (PMC)

Bilateral Striatal Necrosis with Polyneuropathy with a Novel SLC25A19 (Mitochondrial Thiamine Pyrophosphate Carrier OMIMI*606521) Mutation: Treatable Thiamine Metabolic Disorder-A Report of Two Indian Cases.

Gowda Vykuntaraju K, Srinivasan Varunvenkat M, Jehta Kapil et al. · Neuropediatrics · 2019

PMID: 31295743Case Report

A novel Y243S mutation in the pyruvate dehydrogenase El alpha gene subunit: correlation with thiamine pyrophosphate interaction.

Benelli C, Fouque F, Redonnet-Vernhet I et al. · J Inherit Metab Dis · 2002

PMID: 12227466Case Report

Thiamine-responsive pyruvate dehydrogenase deficiency in two patients caused by a point mutation (F205L and L216F) within the thiamine pyrophosphate binding region.

Naito Etsuo, Ito Michinori, Yokota Ichiro et al. · Biochim Biophys Acta · 2002

PMID: 12379317Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Thiamine pyrophosphate (substance)
SNOMED CT: 259661002
UMLS CUI: C0039848

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.